Keep up to date with the latest developments from CERSI-PGx, including news articles, research publications, workshops, and events. This page provides timely information for researchers, industry professionals, regulators, and the public interested in pharmacogenomics.
- Latest Publications
- Upcoming Events
- Past Events Archive
LinkedIn Feed
News & Events
-
CERSI-PGx 5th Guideline is published!
We are pleased to share the news that our guideline on MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity has been published in the BCJP. Huge… read article →
-
Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study | The Pharmacogenomics Journal
We are delighted that our WP5 leads John McDermott and Ramona Moldovan along with colleagues have published an article in the Pharmacogenomics Journal. DTC PGx… read article →
-
The UK Industry PGx Regulatory Portal Product Discovery Report
Presents a comprehensive analysis and vision for a digital regulatory portal designed to streamline the compliance journey for pharmacogenomic (PGx) testing companies within the UK… read article →
-
CERSI-PGx Guideline UGT1A1 genotype testing for irinotecan published!
Today sees the publication of the 4th UK CERSI-PGx guideline on the use of UGT1A1 genotype testing to support the safe prescribing of irinotecan. Irinotecan… read article →
-
CERSI-PGx Commercial Laboratory Workshop
Date Confirmed: Invitation to CERSI-PGx Commercial Laboratory Workshop Tues 30th June 1.00 – 2.30pm Invitation to CERSI-PGx Commercial Laboratory WorkshopAre you a commercial laboratory based in… read article →
-
New Module Launched on CERSI-PGx Training and Education Platform
Responsive Regulatory Action from Signals in Post-Marketing Surveillance — Toxicity Case Studies This module addresses the significance of post-marketing pharmacogenomic (PGx) surveillance and its role… read article →
Learn more about each work package →
- WP1 – Developing UK-Based Guidelines
- WP2 – Pathway for Industry Pharmacogenomic Testing
- WP3 – Education and Training
- WP4 – Health Economics of PGx
- WP5 – Patient and Public Engagement